Moderna: Oddo BHF maintains 'buy' rating
(CercleFinance.com) - Oddo BHF maintains its Outperform rating on Moderna shares, with an unchanged price target of $205.
At a presentation yesterday, the laboratory forecast sales of between $8 and $15 billion for its respiratory division (Covid, VSR, Flu) by 2027, and between $10 and $15 billion in Oncology, Rare Diseases and Latent Viruses from 2028.
"The consensus and we ourselves are, to date, far from these ambitions, recording respectively $8.7 billion and $15.8 billion in 2028", says Oddo BHF, which considers the laboratory's targets to be "extremely ambitious but achievable".
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.